Mitigating influenza morbidity and mortality in immunosuppressed patients requires timely preventative and therapeutic decisions. Healthcare professionals now have greater options for diagnostics and treatment.
The decision to use antivirals for post-exposure influenza chemoprophylaxis is multifaceted. As we anticipate a resurgence of influenza activity this year, how will you leverage the expanding antiviral armamentarium for prevention?
As we anticipate a resurgence of influenza activity this year, healthcare professionals must refocus on prevention and treatment in the pediatric population. Effective mitigation strategies can benefit both children and adults.